Clinical translation of interstitial chemophototherapy with light-activated nanoparticulate doxorubicin

Ended Project Grant Awarded Last action

Award ID
SB1CA288098
Recipient
Awarding agency
Obligated
$249,873

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date
Originally
Place of performance
New York, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
POP BIO's goal is to commercialize interstitial chemo-phototherapy (I-CPT) as a new therapeutic option for locally advanced liver cancers. Doxorubicin (DOX) can be actively loaded into long circulating, serum-stable, porphyrin- phospholipid (POP) liposomes and be released with 665-NM laser light (PHOTODOX). This approach leads to vastly enhanced drug accumulation in irradiated tissues, resulting in ultrapotent tumor ablation. In the phase I sttr, we employed this dosimetry-treatment planning platform to guide light administration of I-CPT with PHOTODOX. We demonstrated that this treatment planning with light dosimetry is effective in ablating large orthotopic hepatocellular carcinoma tumors in rats. The phase II sttr focuses on optimizing treatment planning with light dosimetry using larger (~50CM3) tumors in woodchucks as well as developing a GLP toxicology package as part of an FDA IND submission based on our pre-IND meeting. POP BIO has previously generated non-GLP toxicity data of PHOTODOX in rats including cursory establishment of the maximum tolerated dose. In 2019, POP BIO held a pre-IND meeting with the FDA, who confirmed the suitability of the 505(B)(2) route for components of PHOTODOX and provided guidance about the required toxicological studies required prior to first-in-human studies. The toxicology program will also generate sera samples in two animal models that need to be analyzed by LC/MS (the request of this application). In this commercial readiness program application we propose to further advance I-CPT with PHOTODOX towards an IND for enabling future clinical studies by assessing the pharmacokinetics of DOX, doxorubicinol (DOX-OL), the major metabolite of DOX, and PPA-lipid, the photoactive excipient of PHOTODOX, as well as the stability of PHOTODOX under accelerated storage conditions. These tasks are required by the FDA as part of our IND package. The sera samples to assess pharmacokinetics have been generated as part of the parent phase II sttr award's GLP toxicology program. Under GLP conditions using LC/MS, the sera concentration of free DOX, liposome entrapped DOX, DOX-OL, and PPA-lipid will be measured. Subsequent pharmacokinetic analysis, as part of this application, will be performed by roswell park's bioanalytics, metabolomics & pharmacokinetics (BMPK) shared resource. The result of this application will be the generation of data directly used in POP BIO's IND package generation. If successful, I-CPT with PHOTODOX stands to benefit the majority of new liver cancer patients, who have inoperable and problematic primary tumors.

Transactions

Action Obligated Date
Amendment $0
Original award $249,873

Quick answers

Who received award SB1CA288098?

SB1CA288098 was awarded to Pop Biotechnologies Inc. by National Cancer Institute (National Institutes of Health) on April 1, 2024.

How much is award SB1CA288098 worth?

$249,873 has been obligated on SB1CA288098.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login